KAST trial shows KIVA system efficacy similar to balloon kyphoplasty for VCF treatment

Written by Anuja Vaidya | April 08, 2015 | Print  |

Results from the KAST trial, involving Benvenue Medical's Kiva VCF Treatment System and its efficacy as compared to balloon kyphoplasty, have been published in Spine.

The randomized, controlled study included 300 patients with one or two painful osteoporotic vertebral compression fractures at 21 medical centers in a number of countries. Patients were blindly randomized to receive treatment using the Kiva system or receiving balloon kyphoplasty.


The study found that the KIVA system successfully met the primary endpoint of non-inferiority to balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures based on a composite of pain relief, return to function and safety.


Examination of secondary endpoints showed that the KIVA system showed superiority in cement usage and site-reported cement leakage as well as a positive trend in adjacent level fracture reduction.


More articles on devices:
University of Delaware Research Fund gives $45k to bone disorder project
Atlas Spine to raise $5M through OfferBoard — 5 key notes
Barclays downgrades Stryker outlook to "underweight" — 5 key notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers